recurrent Platinum-resistant Epithelial Ovarian Cancer

DBCOND0128069Endocrine System Diseases Neoplasms

recurrent Platinum-resistant Epithelial Ovarian Cancer is the indication for 1 drug in DrugBank. It is covered by 6 curated, structured indications.

Classified under: Endocrine System Diseases
Neoplasms
Neoplasms, Glandular and Epithelial
Reproductive tract neoplasms NEC
Urogenital Diseases
Indicated drugs: Bevacizumab

What you can answer from here — as of October 24, 2026

1Indicated drugWith each drug's targets and mechanism

Listed above

6Structured indicationsPopulation, line of therapy, route and combination as fields, not prose

1Clinical trialPhase, status and sponsor resolved per trial

1Drug reporting it as an adverse effectWith incidence where the label states it

Which approved drugs for recurrent Platinum-resistant Epithelial Ovarian Cancer share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account